Viatris (VTRS) Gross Margin (2020 - 2026)
Viatris (VTRS) posted Gross Margin of 38.77% for Q2 2026, up 17.83% on a QoQ basis from 32.9% in Q1 2026, and up 156.0% year-over-year from 15.14% in Q2 2025.
Powered by 
Analysis
Viatris (VTRS) Gross Margin (2020 - 2026) Analysis & Trends
Viatris has reported Gross Margin for 7 years, with the latest figure at 38.77% in Q2 2026.
- On a quarterly basis, Gross Margin rose 156.0% year-over-year to 38.77% in Q2 2026; TTM through Jun 2026 was 34.83%, a 178.0% decrease from a year earlier, with the FY2025 full-year figure at 35.06%, down 309.0% from the prior year.
- Gross Margin was 38.77% for Q2 2026 at Viatris, up from 32.9% in the prior quarter.
- The five-year high for Gross Margin was 42.91% in Q3 2023, with the low at 30.99% in Q4 2025.
- Average Gross Margin over 5 years is 38.38%, with a median of 38.83% recorded in 2024.
- The sharpest annual moves came in 2022 and 2024: Gross Margin jumped 1681 bps in 2022, then tumbled 717 bps in 2024.
- Over 5 years, Gross Margin stood at 32.87% in 2022, then grew by 27 bps to 41.6% in 2023, then dropped by 17 bps to 34.44% in 2024, then fell by 10 bps to 30.99% in 2025, then advanced by 25 bps to 38.77% in 2026.
- The last three Gross Margin figures came in at 38.77% (Q2 2026), 32.9% (Q1 2026), and 30.99% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 95.97% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.77% |
| Mar 31, 2026 | 32.90% |
| Dec 31, 2025 | 30.99% |
| Sep 30, 2025 | 36.48% |
| Jun 30, 2025 | 37.21% |
| Mar 31, 2025 | 35.68% |
| Dec 31, 2024 | 34.44% |
| Sep 30, 2024 | 38.90% |
| Jun 30, 2024 | 38.07% |
| Mar 31, 2024 | 41.05% |
| Dec 31, 2023 | 41.60% |
| Sep 30, 2023 | 42.91% |
| Jun 30, 2023 | 41.05% |
| Mar 31, 2023 | 41.36% |
| Dec 31, 2022 | 32.87% |
| Sep 30, 2022 | 42.87% |
| Jun 30, 2022 | 41.37% |
| Mar 31, 2022 | 42.25% |
| Dec 31, 2021 | 35.62% |
| Sep 30, 2021 | 34.70% |